Klotz U, Beil W, Gleiter C, Drewelow B, Garbe E, Gillessen A, Mutschler E
Dr.-Margarete-Fischer-Bosch-Institut für Klinische Pharmakologie, Stuttgart.
Internist (Berl). 2003 Nov;44(11):1444-9. doi: 10.1007/s00108-003-1045-y.
During the last few years 3 important drugs (terfenadine, mibefradil, cisapride) had to been withdrawn from the market because of serious drug-drug interactions. Polypragmacy, not only in advanced age, is often applied. Consequently the possibility of pharmacokinetic and/or pharmacodynamic drug interactions has always to be taken into account which can cause adverse effects, therapeutic failures, hospital admissions and extra costs. Clinically relevant interactions can be observed especially on the level of drug metabolism and transport. Both pharmacokinetic processes can be induced or inhibited by numerous agents. Taking proton pump inhibitors as an example it could be shown that the various compounds can differ in their interaction potential.
在过去几年中,3种重要药物(特非那定、米贝拉地尔、西沙必利)因严重的药物相互作用而不得不退出市场。多药合用的情况很常见,不仅在老年人中。因此,必须始终考虑药代动力学和/或药效学药物相互作用的可能性,这可能导致不良反应、治疗失败、住院和额外费用。尤其在药物代谢和转运水平上可观察到临床相关的相互作用。这两个药代动力学过程都可被多种药物诱导或抑制。以质子泵抑制剂为例,可以看出不同的化合物在相互作用潜力方面存在差异。